Market Cap | 679.70M | P/E | - | EPS this Y | -19.50% | Ern Qtrly Grth | - |
Income | -117.25M | Forward P/E | -5.08 | EPS next Y | 4.90% | 50D Avg Chg | -31.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | 6.00% |
Dividend | N/A | Price/Book | 3.05 | EPS next 5Y | - | 52W High Chg | -56.00% |
Recommedations | 1.90 | Quick Ratio | 7.74 | Shares Outstanding | 35.89M | 52W Low Chg | 218.00% |
Insider Own | 25.10% | ROA | -47.89% | Shares Float | 19.44M | Beta | -0.54 |
Inst Own | 86.85% | ROE | -84.42% | Shares Shorted/Prior | 13.82M/11.20M | Price | 19.20 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 853,767 | Target Price | 54.43 |
Oper. Margin | - | Earnings Date | Apr 1 | Volume | 641,861 | Change | -7.51% |
Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Oppenheimer | Outperform | Apr 3, 24 |
JP Morgan | Neutral | Apr 2, 24 |
HC Wainwright & Co. | Buy | Apr 1, 24 |
Truist Securities | Buy | Apr 1, 24 |
HC Wainwright & Co. | Buy | Mar 6, 24 |
Truist Securities | Buy | Feb 6, 24 |
Citigroup | Buy | Dec 8, 23 |
EF Hutton | Buy | Aug 1, 23 |
HC Wainwright & Co. | Buy | Aug 1, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
A2A Pharmaceuticals, Inc. | 10% Owner 10% Owner | May 12 | Sell | 33.84 | 25,000 | 846,000 | 3,625,000 | 05/17/23 |
A2A Pharmaceuticals, Inc. | 10% Owner 10% Owner | May 08 | Sell | 34.25 | 250,000 | 8,562,500 | 3,650,000 | 05/10/23 |
A2A Pharmaceuticals, Inc. | 10% Owner 10% Owner | Apr 20 | Sell | 29.1188 | 200,000 | 5,823,760 | 3,900,000 | 04/26/23 |
A2A Pharmaceuticals, Inc. | 10% Owner 10% Owner | Mar 31 | Sell | 31.25 | 200,000 | 6,250,000 | 4,100,000 | 04/06/23 |
A2A Pharmaceuticals, Inc. | 10% Owner 10% Owner | Aug 16 | Buy | 13.872 | 30,684 | 425,648 | 4,300,000 | 08/19/22 |
A2A Pharmaceuticals, Inc. | 10% Owner 10% Owner | Jul 21 | Sell | 11.21 | 34,658 | 388,516 | 4,330,684 | 07/25/22 |
A2A Pharmaceuticals, Inc. | 10% Owner 10% Owner | Jun 24 | Sell | 11.76 | 34,658 | 407,578 | 4,365,342 | 06/28/22 |
Valle Franco | Chief Financial Offi.. Chief Financial Officer | Jan 14 | Buy | 8.6767 | 10,000 | 86,767 | 10,000 | 01/18/22 |